Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.
EP. 1: Current Treatment Options for Patients with NSCLC
Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.
EP. 2: Strategies for Monitoring Patients with NSCLC
Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.
EP. 3: Two Key Uses for ctDNA in the Clinical Setting
Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.
EP. 4: Review of Recent Data on ctDNA From ASCO 2022
A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.
EP. 5: Future Implications of ctDNA in the Management of NSCLC
A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC